The Democratic-controlled US House passed Speaker Nancy Pelosi’s controversial drug pricing bill on 12 December essentially along party lines, as expected. But consideration in the Senate won’t happen anytime soon. Whether it happens at all may depend on whether Democrats pick up more seats in that chamber in the 2020 elections.
US Government Drug Pricing ‘Negotiation:’ Where We Go From Here
House passes Democratic bill authorizing the federal government to negotiate drug prices in Medicare. While the exercise has sharpened the debate over how prices feed innovation, the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Our table highlights the key provisions of HR 3 and other pending pricing legislation.
More from Pricing Debate
• By
Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.
• By
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.
• By
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.
• By
Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.
More from Market Access
• By
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.
• By
Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.